Table 1 Growth inhibitory activities (GI50)(μg/ml) of various anti-cancer agents against 10 human lung cancer cell lines – Set 1
From: Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
Drug | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
|---|---|---|---|---|---|---|---|---|---|---|
| Â | PC7 | PC9 | PC14 | A549 | Lu65 | LK-2 | H69 | N231 | Lu135 | SBC-3 |
CDDP | 4.55 | 3.53 | 2.86 | 5.46 | 3.39 | 4.72 | 1.64 | 1.25 | 0.22 | 4.84 |
SN38 | 5.05 | 3.45 | 3.79 | 6.80 | 0.48 | 4.25 | 0.77 | 0.66 | 0.05 | 0.07 |
VIN | 2.64 | 1.43 | >10 | >10 | 0.06 | 0.02 | 0.02 | 0.01 | 0.02 | 0.51 |
DOC | 2.46 | 21.34 | 20.38 | 21.31 | 3.61 | 26.31 | 4.72 | 6.04 | 0.53 | >50 |
GEM | <0.05 | 14.28 | >500 | >500 | 79.53 | 54.61 | 3.73 | 3.88 | <0.05 | <0.05 |
5FU | 2.76 | 5.84 | >10 | >10 | 8.76 | >10 | >10 | >10 | 5.68 | 0.51 |
CBDCA | 95 | 70 | >100 | 46.3 | 71 | 0.225 | 7.54 | 45 | 61 | 3.5 |
PAC | 6.7 | 39 | 34 | 51 | 34 | 20 | <0.001 | 7 | 5.5 | 0.5 |